OakChart

Alkermes plc

ALKSHealthcare·Drug Manufacturers - Specialty & Generic·Ireland·Mid·NASD·Nov 11 • 1:03 PM ET

46.99+0.52 (1.13%)
2026-11-11 19:03 CET
Market cap
7,809.00 USD m
Revenue, TTM
1,753.60 USD m
Net income, TTM
-0.35 USD m
Free cash flow, TTM
227.37 USD m
EPS diluted, TTM
-0.01
P/E
-
Compare

Price

ALKS against its 20, 50 and 200-day averages
2050200beat
30.0040.0050.003.9M7.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALKSclose 46.9920-day 44.5550-day 43.67200-day 41.0046.9952w high

15.6% under the 52-week high of 55.67 on 7 Jul 2026. 52-week low 27.00 on 18 Mar 2026. Last 15 sessions, 10.3% high to low

Profile

ALKS
52-week range, 70% of the way up
27.0055.67

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

IndexRUT
Employees2050
IPOJul 16, 1991
Beta0.28
ATR, 14d1.58
Rel volume0.29
Short float12.05%
Insider own2.98%
Inst own105.10%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap7.90B
Enterprise Value8.71B
Income-0.35M
Sales1.75B
Book/sh11.10
Cash/sh4.50
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees2050
IPOJul 16, 1991

Ratios

P/E-
Forward P/E81.73
PEG-
P/S4.50
P/B4.23
P/C10.45
P/FCF34.73
EV/EBITDA50.25
EV/Sales4.97
Quick Ratio2.02
Current Ratio2.42
Debt/Eq0.84
LT Debt/Eq0.82
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.01
EPS next Y0.57
EPS next Q-0.22
EPS this Y-136.84%
EPS next Y209.13%
EPS next 5Y-11.42%
EPS past 3/5Y- -
Sales past 3/5Y9.90% 7.28%
EPS Y/Y TTM-100.08%
Sales Y/Y TTM15.27%
EPS Q/Q-81.19%
Sales Q/Q21.80%
EarningsNov 03 BMO
EPS/Sales Surpr.210.02% 3.59%

Ownership

Insider Own2.98%
Insider Trans-2.31%
Inst Own105.10%
Inst Trans2.29%
ROA-0.01%
ROE-0.02%
ROIC-0.01%
Gross Margin79.43%
Oper. Margin5.29%
Profit Margin-0.02%
SMA205.49%
SMA507.62%
SMA20014.63%
Trades-

Technical

Shs Outstand168.03M
Shs Float163.04M
Short Float12.05%
Short Ratio10.54
Short Interest19.65M
52W High55.67 -15.59%
52W Low27.00 74.05%
Volatility4.09% 3.68%
ATR (14)1.58
RSI (14)64.40
Beta0.28
Rel Volume0.29
Avg Volume1.86M
Volume310,645

Performance

Perf Week2.40%
Perf Month18.28%
Perf Quarter-4.97%
Perf Half Y20.77%
Perf YTD67.95%
Perf Year38.99%
Perf 3Y112.40%
Perf 5Y106.17%
Perf 10Y-13.60%
Recom1.59
Target Price58.41
Prev Close46.47
Price46.99
Change %1.13%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedTTruistBuy$55+17.0%
Jul 13, 2026ResumedJJP MorganNeutral$60+27.7%
Jun 29, 2026DowngradeBBofA SecuritiesNeutral → Underperform$38-19.1%
Feb 24, 2026InitiatedWWolfe ResearchOutperform$45-4.2%
Nov 11, 2025InitiatedTTruistBuy$50+6.4%
Sep 26, 2025UpgradeRRBC Capital MktsSector Perform → Outperform$44-6.4%
Sep 03, 2025InitiatedWWells FargoOverweight$44-6.4%
Jul 15, 2025InitiatedGGoldmanBuy$43-8.5%
Jun 17, 2025UpgradeUUBSNeutral → Buy$42-10.6%
May 28, 2025InitiatedNNeedhamBuy$45-4.2%

Peers

Mkt cap
TickerCompanyMkt cap
NBIXNeurocrine Biosciences Inc17.53B
INDVIndivior Pharmaceuticals Inc5.97B
JAZZJazz Pharmaceuticals plc15.73B
TEVATeva- Pharmaceutical Industries Ltd49.99B
TAKTakeda Pharmaceutical Co ADR66.23B
SUPNSupernus Inc6.11B
AXSMAxsome Therapeutics Inc7.84B
HRMYHarmony Biosciences Holdings Inc2.01B
ACADAcadia Pharmaceuticals Inc3.18B
JNJJohnson & Johnson668.95B

Insider trading

latest 14 of 69
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gaffin David JosephEVP, CLO, Alkermes, Inc.Nov 03 '26Sale46.172,03593,956219,353Nov 03 07:18 PM
Gaffin David JosephOfficerNov 03 '26Proposed Sale46.172,03593,956Nov 03 04:08 PM
Gaffin David JosephEVP, CLO, Alkermes, Inc.Oct 02 '26Sale41.032,03483,455221,388Oct 02 06:22 PM
Gaffin David JosephOfficerOct 02 '26Proposed Sale41.032,03483,455Oct 02 04:04 PM
Gaffin David JosephEVP, CLO, Alkermes, Inc.Sep 03 '26Sale48.012,03497,652223,422Sep 03 06:32 PM
Gaffin David JosephOfficerSep 03 '26Proposed Sale48.012,03497,652Sep 03 04:58 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerSep 01 '26Option Exercise24.595,000122,95074,389Sep 01 07:08 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerSep 01 '26Sale46.999,000422,87465,389Sep 01 07:08 PM
Hopkinson Craig C.OfficerSep 01 '26Proposed Sale46.999,000422,874Sep 01 04:10 PM
Nichols Christian ToddSVP, Chief Commercial OfficerAug 17 '26Sale49.237,576372,937102,193Aug 17 06:53 PM
Nichols Christian ToddOfficerAug 17 '26Proposed Sale49.237,576372,937Aug 17 04:50 PM
snyderman nancy lynn MDDirectorAug 03 '26Option Exercise46.7244,4722,077,73259,867Aug 03 07:16 PM
snyderman nancy lynn MDDirectorAug 03 '26Sale50.3544,4722,239,07615,395Aug 03 07:16 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerAug 03 '26Option Exercise24.485,000122,40478,389Aug 03 07:12 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B

News

latest 14 of 206
  • Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress (Business Wire)
  • Alkermes to Present at Upcoming Investor Conferences (Business Wire)
  • Alkermes Beats Its Own Guidance, But Lybalvi Pricing Dilution And Takeda's Orexin Launch Cloud A Stronger Quarter (Earnings Whispers)
  • Alkermes: Q3 Earnings Snapshot (Associated Press)
  • Alkermes plc Reports Third Quarter 2026 Financial Results (Business Wire)
  • Loading…
  • Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) (Business Wire)
  • Alkermes Faces A Planned Profit Dip As R&D Ramp Tests Orexin Optimism (Earnings Whispers)
  • Alkermes to Report Third Quarter Financial Results on November 3, 2026 (Business Wire)
  • Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst calls (The Fly)
  • Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research (Business Wire)
  • An orexin drugs proof-of-concept in ADHD; Cues unwarranted share slide (BioPharma Dive)
  • How Alkermes Used Its Narcolepsy Playbook In ADHD - And Seemingly Won (Investor's Business Daily)
  • Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 (InvestorsHub)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-030.090-0.0820.090480.13463.4815
2026Q22026-07-280.000-0.0280.003496.01457.3816
2026Q12026-05-05-0.400-0.546-0.400392.91363.0615
2025Q42026-02-250.2900.4100.291384.55378.9412
2025Q32025-10-280.6840.3690.491394.19356.8912
2025Q22025-07-290.6680.3560.517390.66341.3612
2025Q12025-05-010.2650.2550.133306.51302.9110
2024Q42025-02-121.0500.7590.880429.99379.3912
2024Q32024-10-240.7200.7010.553378.14380.8810
2024Q22024-07-240.7000.7040.534399.13393.38
2024Q12024-05-010.4300.5830.213350.37360.268
2023Q42024-02-150.2200.4470.663377.48362.229
2023Q32023-10-250.5950.3960.278380.94362.318
2023Q22023-07-260.5110.3671.382617.4458.078
2023Q12023-04-260.0100.005-0.254287.6283.418
2022Q42023-02-160.1400.045-0.172304.67289.769

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.6600.395-1.2521,1711,164
2020FY0.4000.357-0.6981,0391,027
2021FY0.7250.585-0.2991,1741,158
2022FY0.3160.231-0.9671,1121,097
2023FY1.4401.5982.0961,6631,649
2024FY2.8902.6212.1701,5581,507
2025FY1.4301.7421.4301,4761,471
2026FY--0.527--1,828
2027FY-0.575--1,933
2028FY-0.994--2,122
2029FY-1.924--2,331
2030FY-2.963--2,618

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0516012461.93441.44483.22
2026Q4S2026-11-0418012459.91440483.22
2026Q4S2026-11-0318011460.47440483.22
2026Q4S2026-10-281801471.79440489.3
2026Q4S2026-10-271801471.79440489.3
2026Q4S2026-10-161801471.78440489.3
2026Q4S2026-10-151801471.87440489.3
2026Q4S2026-10-141701471.66440489.3
2026Q4S2026-10-111701471.66440489.3
2026Q4S2026-10-0917212471.66440489.3
2026Q4S2026-10-0717212471.84440489.3
2026Q4S2026-10-0617211472.06440489.3
2026Q4S2026-10-0317211472.05440489.3
2026Q4S2026-09-2317212472.05440489.3

Estimate history

EPS, annual-1.03-0.898-1.252-0.698-0.299-0.9672.0962.171.432-0.0137
Period201720182019202020212022202320242025TTM
EPS, quarterly0.5530.880.1330.5170.4910.291-0.40.0030.092
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual903.3741094.2741170.9471038.7561173.7511111.7951663.4051557.6321475.8991753.6
Period201720182019202020212022202320242025TTM
Sales, quarterly378.143429.986306.51390.657394.185384.547392.911496.009480.132
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual154.009155.757157.779159.161161.937164.377166.98162.177165.607168.03
Period201720182019202020212022202320242025MRQ
Shares, quarterly161.776162.177164.853165.055165.104165.607166.462167.541168.03
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,753.601,475.901,557.631,663.401,111.801,173.751,038.761,170.951,094.27
Cost of Goods Sold Incl. D&A360.78202.06252.13298.33265.13247.74232.87234.74253.49
Gross Profit1,392.821,273.841,305.501,365.08846.66926.02805.89936.20840.79
Selling, General and Administrative Excl. Other1,300.141,019.89884.86950.96852.75955.30918.321,011.68934.21
Research and Development423.72318.36239.63261.21262.00394.33379.49412.23413.51
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income92.68253.96420.64414.12-6.09-29.29-112.43-75.48-93.43
Interest Expense86.6412.2822.5823.0313.0411.228.6613.6013.14
Unusual Expense28.480.000.800.0021.750.45-3.94122.8027.60
Net Income Before Taxes11.31291.45443.75421.52-31.13-39.31-96.54-197.06-126.97
Income Taxes11.6649.7971.61-97.642.028.8614.32-0.4412.34
Consolidated Net Income-0.35241.66372.14519.16-33.15-48.17-110.86-196.62-139.31
Net Income From Continuing Operations-0.35241.66372.14519.16-33.15-48.17-110.86-196.62-139.31
Net Income-0.35241.66367.07355.76-158.27-48.17-110.86-196.62-139.31
EPS (Recurring)0.111.432.172.10-0.87-0.30-0.72-0.70-0.77
EPS (Basic, Before Extraordinaries)-0.001.472.222.14-0.97-0.30-0.70-1.25-0.90
EPS (Diluted)-0.011.432.172.10-0.97-0.30-0.70-1.25-0.90
EBITDA173.39281.12449.17489.0571.7749.37-30.574.9310.23
Non-Operating Income (Expense)33.7649.7746.4930.439.751.6520.6014.827.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense95.1977.9976.3473.2569.2663.9665.8273.7183.23
Price To Earnings Ratio--14.6522.47-----
Price To Sales Ratio4.083.203.122.833.853.193.052.744.18
Gross Margin79.4386.3183.8182.0776.1578.8977.5879.9576.84
Operating Margin5.2917.2127.0024.90-0.55-2.50-10.82-6.45-8.54
Net Margin-0.0216.3723.5721.39-14.24-4.10-10.67-16.79-12.73
Shares Outstanding168.03165.61162.18166.98164.38161.94159.16157.78155.76
Market Capitalization7,809.007,809.004,653.454,629.284,224.663,700.983,124.163,161.954,511.86

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue480.13496.01392.91384.55394.19390.66306.51429.99
Cost of Goods Sold Incl. D&A115.82122.5074.9547.5152.9950.9650.6063.63
Gross Profit364.31373.51317.96337.04341.19339.70255.91366.36
Selling, General and Administrative Excl. Other326.22328.75366.24278.93252.11246.72242.12203.67
Research and Development119.22111.12101.6491.7480.3475.8770.4256.67
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income38.0944.77-48.2858.1089.0892.9813.79162.69
Interest Expense27.5525.9320.8912.280.000.000.004.65
Unusual Expense2.0726.410.000.000.000.000.000.80
Net Income Before Taxes14.74-1.88-61.9360.38100.75104.8425.49169.89
Income Taxes-1.55-2.384.5511.0417.9817.743.0224.15
Consolidated Net Income16.290.50-66.4849.3482.7687.1022.46145.74
Net Income From Continuing Operations16.290.50-66.4849.3482.7687.1022.46145.74
Net Income16.290.50-66.4849.3482.7687.1022.46146.50
EPS (Recurring)0.100.11-0.400.290.490.520.130.88
EPS (Basic, Before Extraordinaries)0.100.00-0.400.300.500.530.140.90
EPS (Diluted)0.090.00-0.400.290.490.520.130.88
EBITDA65.2575.04-28.8561.9597.16100.8021.21169.53
Non-Operating Income (Expense)6.265.707.2514.5511.6611.8611.7012.65
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense21.1324.6028.7020.7619.4819.7218.0216.39
Price To Earnings Ratio-58.2524.6813.8414.4013.6215.1514.65
Price To Sales Ratio4.085.453.763.213.323.203.683.08
Gross Margin75.8875.3080.9287.6586.5686.9683.4985.20
Operating Margin7.939.03-12.2915.1122.6023.804.5037.84
Net Margin3.390.10-16.9212.8321.0022.307.3334.07
Shares Outstanding168.03167.54166.46165.61165.10165.05164.85162.18
Market Capitalization7,809.008,732.995,892.744,620.004,952.344,717.825,369.514,653.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,319.42751.67773.49608.47536.31635.03534.98539.29433.50
Short Term Receivables334.02389.52333.18296.90326.56289.54265.47300.45233.59
Inventories196.62182.89186.41181.42150.34125.74101.8090.2093.28
Other Current Assets79.0991.28192.4343.5348.9760.6659.7253.3148.29
Total Current Assets1,929.161,415.361,485.511,130.311,062.171,110.97961.97983.25808.66
Net Property, Plant & Equipment298.93311.81318.40320.46456.68481.72374.55309.99284.74
Total Investments and Advances0.1473.1539.89131.61235.5330.9885.2986.24157.21
Long-Term Note Receivable----13.3619.4013.39--
Intangible Assets83.8483.9285.02120.71166.92204.06243.52283.87349.04
Deferred Tax Assets169.08154.84195.89114.5781.8386.2396.5685.8198.56
Other Assets49.1016.5011.52146.327.9916.3630.1475.8499.02
Total Assets2,530.262,055.572,136.221,963.982,024.481,949.731,805.401,825.011,797.23
Short Term Debt Incl. Current Port. of LT Debt6.756.178.7512.8819.2418.5711.312.843.00
Accounts Payable107.9545.6365.6532.8455.7246.0354.2639.7755.53
Other Current Liabilities428.74413.40445.82452.02396.32373.65325.54297.16232.60
Total Current Liabilities543.44465.20520.22497.74471.29438.26391.11339.77291.12
Long Term Debt63.2569.37363.44366.56396.97391.58279.64276.46278.44
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities43.26--------
Other Liabilities61.0156.0249.8855.9343.6552.9149.2137.4824.86
Total Liabilities710.96590.59933.54920.23911.90882.75719.96653.72594.42
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,819.301,464.981,202.691,043.751,112.581,066.981,085.441,171.291,202.81
Total Shareholders Equity1,819.301,464.981,202.691,043.751,112.581,066.981,085.441,171.291,202.81
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,819.301,464.981,202.691,043.751,112.581,066.981,085.441,171.291,202.81
Total Liabilities & Stockholders Equity2,530.262,055.572,136.221,963.982,024.481,949.731,805.401,825.011,797.23
Book Value Per Share10.999.037.206.356.876.706.887.527.81
Tangible Book Value Per Share10.488.526.695.625.845.425.345.705.54
Full-Time Employees2,0501,8002,1002,2802,2112,2452,2352,3002,000
Price to Book Ratio4.193.603.414.053.332.932.923.866.97
Return on Assets10.5417.7625.32-1.66-2.42-5.90-10.83-7.69-8.96
Return on Equity14.7227.9046.22-3.07-4.42-10.30-17.43-11.74-13.10
Return on Invested Capital12.8423.9222.72-11.22-3.19-7.60-14.40-9.62-10.66
Quick Ratio3.192.652.501.911.932.252.202.632.46
Current Ratio3.553.042.862.272.252.532.462.892.78

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-0.35241.66367.07355.76-158.27-48.17-110.86-196.62-139.31
Depreciation80.7127.1628.5374.9377.8678.6581.8580.41103.66
Other Funds (Non Cash)229.41104.03101.15107.23121.5391.7088.73123.20131.73
Funds from Operations308.38401.63537.27438.028.34127.2669.716.67106.70
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-65.40119.12-98.15-36.6612.71-25.5513.1365.41-7.42
Cash from Operating Activities242.99520.75439.12401.3521.04101.7282.8472.0899.28
Capital Expenditures-15.62-40.42-33.48-48.05-38.26-29.02-42.22-90.94-69.43
Net Assets From Acquisitions-2,085.070.000.000.000.000.000.00-8.88-
Sale of Fixed Assets and Businesses1.072.790.460.350.000.290.640.900.51
Purchase or Sale of Investments362.55333.12-176.26101.05-28.04-45.4123.46-52.9246.73
Purchase of Investments-121.24-364.37-486.55-254.47-309.67-340.42-229.54-277.52-397.73
Sale Or Maturity of Investments483.79697.49310.29355.52281.63295.01253.00224.60444.46
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.0097.980.001.767.946.6410.000.00
Cash from Investing Activities-1,737.08295.50-111.3153.36-64.54-66.20-11.48-141.83-22.20
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.0712.38-202.35-11.711.438.750.679.611.25
Repurchase of Common Pref Stock-58.73-31.03-229.92-28.47-18.20-16.57-7.70-9.32-19.62
Sale of Common Pref Stock66.8043.4127.5716.7619.6325.328.3718.9320.88
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net1,495.330.00-291.79-3.00-3.0020.32-2.84-2.84-2.13
Change in Long Term Debt1,495.330.00-291.79-3.00-3.0020.32-2.84-2.84-2.13
Issuance of Long Term Debt1,554.120.000.000.000.0022.570.000.000.00
Reduction of Long Term Debt-58.790.00-291.79-3.00-3.00-2.25-2.84-2.84-2.13
Net Financing Active Other Cash Flow5.550.000.00-275.000.000.000.000.00-0.74
Other Financing Activities Uses5.550.000.00-275.000.000.000.000.00-0.74
Cash from Financing Activities1,508.9512.38-494.14-289.71-1.5729.07-2.176.76-1.62
Net Change in Cash14.87828.63-166.32165.00-45.0764.5869.19-62.9975.47
Free Cash Flow227.37480.33405.64353.31-17.2173.6940.62-18.8629.85
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow31.439.8312.0013.33-50.8077.99-153.35
Deferred Taxes & Investment Tax Credit-28.7740.52-99.90-32.805.089.98-0.3210.62

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments755.46656.58511.861,319.421,111.111,015.74
Short Term Receivables459.09456.48407.63334.02355.11356.33
Inventories261.10298.96336.70196.62191.00191.92
Other Current Assets105.09110.89102.4579.0984.4471.30
Total Current Assets1,580.741,522.911,358.641,929.161,741.661,635.29
Net Property, Plant & Equipment294.75294.39298.83298.93326.11319.93
Total Investments and Advances32.1135.0526.360.1427.8738.27
Intangible Assets2,334.282,355.732,380.0783.8483.8683.88
Deferred Tax Assets120.77123.04134.81169.08130.34155.53
Other Assets72.8862.0059.3649.1019.6619.91
Total Assets4,435.524,393.124,258.082,530.262,329.512,252.81
Short Term Debt Incl. Current Port. of LT Debt34.0933.9834.086.756.636.46
Accounts Payable107.69142.86102.36107.9568.0099.21
Other Current Liabilities510.16485.25463.06428.74399.73400.29
Total Current Liabilities651.93662.09599.50543.44474.36505.96
Long Term Debt1,536.991,538.591,547.5863.2564.9766.22
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities177.21179.57181.9243.26--
Other Liabilities204.67204.32177.5461.0156.7556.05
Total Liabilities2,570.802,584.572,506.55710.96596.08628.23
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,864.721,808.551,751.531,819.301,733.431,624.58
Total Shareholders Equity1,864.721,808.551,751.531,819.301,733.431,624.58
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,864.721,808.551,751.531,819.301,733.431,624.58
Total Liabilities & Stockholders Equity4,435.524,393.124,258.082,530.262,329.512,252.81
Book Value Per Share11.1010.7910.5210.9910.509.84
Tangible Book Value Per Share-2.79-3.27-3.7810.489.999.33
Full-Time Employees---2,050--
Price to Book Ratio4.194.983.222.673.053.12
Return on Assets-0.011.994.8210.5415.0815.61
Return on Equity-0.023.859.3614.7222.3523.94
Return on Invested Capital0.480.01-2.022.624.605.15
Quick Ratio2.021.851.703.193.272.85
Current Ratio2.422.302.273.553.673.23

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income16.290.50-66.4849.3482.7687.10
Depreciation27.1630.2819.433.858.087.82
Other Funds (Non Cash)59.0492.8450.3527.1925.8227.94
Funds from Operations102.50132.72-5.4978.66148.05119.45
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-9.0212.46-160.2591.41-46.3830.76
Cash from Operating Activities93.48145.18-165.74170.07101.67150.20
Capital Expenditures-3.40-8.15-4.090.02-17.31-13.02
Net Assets From Acquisitions0.000.00-2,085.070.000.000.00
Sale of Fixed Assets and Businesses0.010.000.011.050.000.03
Purchase or Sale of Investments23.395.7412.15321.2710.58-16.23
Purchase of Investments-20.60-14.35-30.45-55.84-114.73-97.82
Sale Or Maturity of Investments43.9920.0942.61377.11125.3181.59
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities19.99-2.41-2,077.00322.35-6.74-29.21
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock13.62-1,485.271,499.58-19.850.622.08
Repurchase of Common Pref Stock0.000.00-27.70-31.030.000.00
Sale of Common Pref Stock13.62-1,485.271,527.2711.180.622.08
Proceedsfrom Stock Options0.00-1,511.561,511.560.000.000.00
Issuance or Reduction of Debt, Net-6.621,501.950.000.000.000.00
Change in Long Term Debt-6.621,501.950.000.000.000.00
Issuance of Long Term Debt45.541,508.580.000.000.000.00
Reduction of Long Term Debt-52.16-6.620.000.000.000.00
Net Financing Active Other Cash Flow-0.67-1.10-23.4430.77-0.31-1.68
Other Financing Activities Uses-0.67-1.10-23.4430.77-0.31-1.68
Cash from Financing Activities6.3217.201,474.5210.910.320.41
Net Change in Cash119.78159.98-768.23503.3395.25121.39
Free Cash Flow90.08137.04-169.83170.0984.36137.19
Price to Free Cash Flow31.4341.0126.509.8810.3010.04

Revenue breakdown

Manufactured Product And Royalty2024: 474.10M 2025: 291.26M
Product2024: 1.08B 2025: 1.18B
Research And Development2024: 3.00K
Foreign Country Excluding Specified Country2024: 146.18M 2025: 102.36M
Ireland2024: 1.29M 2025: 754.00K
United States2024: 1.41B 2025: 1.37B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.05%19.6M163.0M1.83M
2026-10-1511.70%19.0M162.8M1.85M
2026-09-3010.95%17.8M162.8M1.78M
2026-09-159.31%15.2M162.8M1.89M
2026-08-319.04%14.7M162.8M1.97M
2026-08-149.07%14.8M162.8M2.09M
2026-07-318.78%14.4M164.1M2.27M
2026-07-159.21%15.0M163.0M2.22M
2026-06-3010.72%17.5M163.0M2.50M
2026-06-1511.02%18.0M162.9M2.31M
2026-05-2910.65%17.4M163.0M2.37M
2026-05-1511.22%18.3M163.0M2.39M
2026-04-3012.08%19.8M163.6M2.24M
2026-04-1512.06%19.7M163.2M2.39M
2026-03-3111.64%19.0M163.3M2.34M
2026-03-1312.62%20.6M163.3M2.00M
2026-02-2711.14%18.2M163.3M1.90M
2026-02-1311.01%17.8M161.8M1.96M
2026-01-3011.77%19.0M161.4M2.25M
2026-01-1513.42%21.7M161.4M2.32M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0029.7033.600.006.3150.000.000.960-0.1980.006
call20.0024.7028.100.004.3240.000.000.947-0.1940.008
call21.0023.7026.600.003.4320.000.000.944-0.1930.008
call22.0022.7025.700.003.4060.000.000.940-0.1910.009
call23.0021.7025.600.004.2130.000.000.937-0.1900.009
call24.0020.7024.200.003.6330.000.000.934-0.1880.010
call25.0019.7023.700.003.8980.000.000.930-0.1860.010
call26.0018.7022.700.003.7070.000.000.926-0.1840.010
call27.0017.7021.700.003.5230.000.000.922-0.1820.011
call28.0016.7020.400.003.1140.000.000.918-0.1800.011
call29.0015.7019.700.003.1750.000.000.914-0.1770.012
call30.0014.7018.700.003.0090.000.000.909-0.1750.012
call31.0013.7017.700.002.8480.000.000.903-0.1720.013
call32.0012.7016.700.002.6920.000.000.898-0.1690.013
call33.0011.7015.400.002.3480.000.000.889-0.1720.014
call34.0010.7014.700.002.3900.000.000.882-0.1680.015
call35.009.7013.400.002.2440.000.000.869-0.1680.016
call36.008.7012.802.502.1561.000.000.866-0.1600.016
call37.007.7011.800.002.0140.000.000.857-0.1560.017
call38.006.8010.809.201.8731.000.000.847-0.1510.017
call39.005.809.704.801.6862.000.000.835-0.1460.018
call40.004.808.403.751.4072.000.000.822-0.1400.019
call41.003.907.804.801.48324.000.000.797-0.1420.021
call42.002.956.503.601.19345.000.000.719-0.2290.025
call43.002.055.703.191.1641580.000.692-0.2200.026
call44.001.154.903.361.08217.000.000.664-0.2140.027
call45.000.454.602.801.19056.000.000.630-0.2020.028
call46.000.053.102.150.93752.000.000.571-0.1860.029
call47.000.003.701.451.11195.000.000.524-0.1980.029
call48.000.001.450.600.84834.000.000.488-0.1760.029
call49.000.000.901.690.61130.000.000.366-0.1180.028
call50.000.001.500.400.7052620.000.318-0.1170.026
call55.000.000.750.251.0706,2700.000.188-0.1180.020
call60.000.002.150.121.3721540.000.156-0.1360.018
call65.000.002.151.751.66520.000.000.135-0.1490.016
call70.000.002.151.101.9415.000.000.121-0.1600.015
call75.000.001.151.302.1736.000.000.112-0.1680.014
call80.000.002.150.702.3738.000.000.105-0.1760.013
put15.000.002.150.355.5135.000.00-0.040-0.1950.006
put20.000.000.950.754.2531.000.00-0.054-0.1900.008
put21.000.001.750.804.0591.000.00-0.057-0.1900.008
put22.000.001.950.003.8430.000.00-0.061-0.1870.009
put23.000.001.750.003.6520.000.00-0.064-0.1860.009
put24.000.001.950.003.4690.000.00-0.067-0.1840.010
put25.000.000.950.003.2760.000.00-0.071-0.1800.010
put26.000.001.950.003.1080.000.00-0.075-0.1780.010
put27.000.002.150.002.9590.000.00-0.079-0.1770.011
put28.000.001.950.002.7910.000.00-0.084-0.1730.011
put29.000.000.950.002.6640.000.00-0.088-0.1730.012
put30.000.002.150.002.5050.000.00-0.093-0.1690.012
put31.000.002.152.702.3671.000.00-0.098-0.1670.013
put32.000.000.950.002.2440.000.00-0.103-0.1640.013
put33.000.002.150.502.1656.000.00-0.111-0.1680.014
put34.000.002.150.002.0460.000.00-0.122-0.1690.015
put35.000.002.151.341.9006.000.00-0.125-0.1600.015
put36.000.002.150.431.7721.000.00-0.134-0.1560.016
put37.000.002.150.331.6463,3420.00-0.143-0.1520.017
put38.000.001.100.421.50612.000.00-0.161-0.1490.018
put39.000.001.350.371.38513.000.00-0.173-0.1440.019
put40.000.001.000.101.25986.000.00-0.181-0.1350.019
put41.000.001.100.771.6933580.00-0.260-0.2230.024
put42.000.002.401.501.5774020.00-0.289-0.2180.025
put43.000.002.552.551.4832480.00-0.316-0.2100.026
put44.000.002.801.501.42655.000.00-0.347-0.2050.027
put45.000.002.801.101.2571720.00-0.386-0.1950.028
put46.000.003.401.331.2950.000.00-0.430-0.1810.029
put47.000.504.000.001.3230.000.00-0.474-0.1930.029
put48.000.454.503.701.36992.000.00-0.509-0.1720.029
put49.001.154.900.001.3020.000.00-0.600-0.1210.029
put50.001.605.607.401.3261.000.00-0.659-0.1160.027
put55.006.8010.307.901.6280.000.00-0.812-0.1120.020
put60.0011.7015.300.002.0380.000.00-0.846-0.1300.017
put65.0016.5020.300.002.3520.000.00-0.866-0.1420.016
put70.0021.3025.300.002.8340.000.00-0.878-0.1520.015
put75.0026.3030.300.003.1020.000.00-0.888-0.1600.014
put80.0031.3035.300.003.3440.000.00-0.895-0.1670.013

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-094Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-094Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-09-218-KCurrent report2026-09-21SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-14SEC
2026-09-168-KCurrent report2026-09-14SEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-038-K/A2026-02-24SEC
2026-07-28S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-288-KCurrent report2026-07-28SEC
2026-07-088-KCurrent report2026-07-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110093.96K1
2026-100083.46K1
2026-0900520.53K2
2026-08003.15M4
2026-0700573.52K2
2026-0600552.81K3
2026-05001.06M3
2026-0400389.92K2
2026-0300769.40K5
2026-02002.42M2
2026-0100262.01K2
2025-1200229.65K2
2025-1100273.44K1

Institutional holders

Manager% owned
BlackRock, Inc.17.54%
BAKER BROS. ADVISORS LP6.01%
VANGUARD PORTFOLIO MANAGEMENT LLC5.69%
STATE STREET CORP5.50%
VANGUARD CAPITAL MANAGEMENT LLC4.51%
PRICE T ROWE ASSOCIATES INC /MD/4.04%
RENAISSANCE TECHNOLOGIES LLC3.88%
GEODE CAPITAL MANAGEMENT, LLC2.65%
Deep Track Capital, LP2.40%
AMERICAN CENTURY COMPANIES INC2.37%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF6.02%
Fidelity Advisor Floating Rate High Income Fund5.82%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
iShares Russell 2000 ETF2.58%
VANGUARD SMALL-CAP INDEX FUND2.29%
Multi-Manager Directional Alternative Strategies Fund1.44%
Invesco Senior Floating Rate Fund1.38%
First Trust NYSE Arca Biotechnology Index Fund1.36%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.36%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.32%

OakChart. ALKS. Cached 15 minutes.